461
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Abstinence from alcohol and alcohol rehabilitation therapy in alcoholic liver disease: a population-based study

, , , , , & show all
Pages 472-478 | Received 27 Dec 2019, Accepted 12 Mar 2020, Published online: 01 Apr 2020

References

  • Kling CE, Perkins JD, Carithers RL, et al. Recent trends in liver transplantation for ALD in the United States. World J Hepatol. 2017;9:315–321.
  • Sheron N, Gilmore I, Parsons C, et al. Projections of alcohol-related deaths in England and Wales–tragic toll or potential prize? Lancet. 2012;379:687–688.
  • Nemtsov AV. Alcohol-related human losses in Russia in the 1980s and 1990s. Addiction. 2002;97(11):1413–1425.
  • Fan JG. Epidemiology of alcoholic and non-alcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):11–17.
  • Potts JR, Goubet S, Heneghan MA, et al. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013;38(6):584–595.
  • Singal AK, Kamath PS, Gores GJ, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12(4):555–564.
  • Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785–790.
  • Altamirano J, Lopez-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis; prediction and impact on long-term survival. Hepatology. 2017;66(6):1842–1853.
  • Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–1628.
  • Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618.
  • Soterakis J, Resnick RH, Iber FL. Effect of alcohol abstinence on survival in cirrhotic portal hypertension. Lancet. 1973;14:65–67.
  • D’Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Digest Dis Sci. 1986;31:468–475.
  • Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 2003;23(1):45–53.
  • Serra MA, Escudero A, Rodríguez F, et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol. 2003;36(2):170–174.
  • Bell H, Jahnsen J, Kittang E, et al. Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scand J Gastroenterol. 2004;39(9):858–863.
  • Alvarez MA, Cirera I, Sola R, et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol. 2011;45(10):906–911.
  • Kalaitzakis E, Wallskog J, Björnsson E. Abstinence in patients with alcoholic liver cirrhosis: a follow-up study. Hepatolog Res. 2008;38(9):869–876.
  • Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognosis. Hepatology. 1987;7:122–128.
  • Xie YD, Feng B, Gao Y, et al. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: a systemic review and meta-analysis. Hepatol Res. 2014;44(4):436–449.
  • Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology. 2017;66(5):1464–1473.
  • Peeraphatdit TB, Kamath PS, Karpyak VM, et al. Alcohol rehabilitation within 30 days of hospital discharge was associated with reduced readmission, relapse and death in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2020;18:477–485.
  • Kamath P, Wiesner R, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;15:101–109.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.